{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:50:32Z","timestamp":1793242232065,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s40272-013-0016-6","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T09:21:24Z","timestamp":1363857684000},"page":"139-150","source":"Crossref","is-referenced-by-count":122,"title":["Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Noor B.","family":"Almandil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macey L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M. C.","family":"Besag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Aitchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"P Jones","year":"2006","unstructured":"Jones P, Barnes TR, Davies L, et al. Randomised controlled trial of the effect of quality of life of second vs. first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006;63:1079\u201387.","journal-title":"Arch Gen Psychiatry"},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1176\/ps.50.2.171","volume":"50","author":"RP Malone","year":"1999","unstructured":"Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in treatment of children and adolescents. Psychiatr Serv. 1999;50:171\u20134.","journal-title":"Psychiatr Serv"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman MG, Binder C, Turgay A. Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behaviour disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243\u201354.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3956(01)00020-6","volume":"35","author":"I Glick","year":"2001","unstructured":"Glick I, Murray S, Hu R, et al. Treatment with atypical antipsychotics: new indications and new population. J Psychiatr Res. 2001;35:187\u201391.","journal-title":"J Psychiatr Res"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","volume":"28","author":"N Nasrallah","year":"2003","unstructured":"Nasrallah N. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28:83\u201396.","journal-title":"Psychoneuroendocrinology"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","volume":"165","author":"RL Findling","year":"2008","unstructured":"Findling RL, Robb A, Nyilas M, et al. A multiple-centre, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432\u201341.","journal-title":"Am J Psychiatry"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","volume":"165","author":"L Sikich","year":"2008","unstructured":"Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder. Am J Psychiatry. 2008;165:1420\u201331.","journal-title":"Am J Psychiatry"},{"issue":"suppl.4","key":"16_CR8","first-page":"4","volume":"69","author":"KD Chang","year":"2008","unstructured":"Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry. 2008;69(suppl.4):4\u20138.","journal-title":"J Clin Psychiatry"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.08m03538","volume":"70","author":"LA Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya LA, Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70:247\u201358.","journal-title":"J Clin Psychiatry"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/chi.0b013e318040b25f","volume":"46","author":"CU Correll","year":"2007","unstructured":"Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systemic review and pooled analysis of short term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687\u2013700.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/adc.2004.050468","volume":"89","author":"ICK Wong","year":"2004","unstructured":"Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89:1131\u20132.","journal-title":"Arch Dis Child"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","volume":"121","author":"F Rani","year":"2008","unstructured":"Rani F, Byrne PJ, Murray ML, Wong ICK, et al. Epidemiological features of antipsychotics prescribing to children and adolescents in primary care in United Kingdom. Pediatrics. 2008;121:1002\u20139.","journal-title":"Pediatrics"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/archpedi.157.10.997","volume":"157","author":"A Martin","year":"2003","unstructured":"Martin A, Leslie D. Trends in psychotropic medications costs for children and adolescents, 1997\u20132000. Arch Pediatr Adolesc Med. 2003;157:997\u20131004.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/CLT-100102873","volume":"39","author":"MJ Burns","year":"2001","unstructured":"Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol. 2001;39:1\u201314.","journal-title":"Clin Toxicol"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/070674370605100803","volume":"51","author":"JW Newcomer","year":"2006","unstructured":"Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480\u201391.","journal-title":"Can J Psychiatry"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","volume":"34","author":"S Kumra","year":"2008","unstructured":"Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60\u201371.","journal-title":"Schizophr Bull"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/cap.2006.16.308","volume":"16","author":"C Fleischhaker","year":"2006","unstructured":"Fleischhaker C, Heister P, Hennighausen K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16:308\u201316.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(02)09678-2","volume":"360","author":"CB Ebbeling","year":"2002","unstructured":"Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public health crisis common sense cure. Lancet. 2002;360:473\u201382.","journal-title":"Lancet"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(94)91163-0","volume":"343","author":"I Lissau","year":"1994","unstructured":"Lissau I, Sorensen TI. Parental neglect during childhood and increased risk of obesity in young adulthood. Lancet. 1994;343:324\u20137.","journal-title":"Lancet"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2337\/diabetes.51.1.204","volume":"51","author":"SR Srinivasan","year":"2002","unstructured":"Srinivasan SR, Myers L, Berenson G. Predictability of childhood adiposity and insulin for developing Insulin resistance syndrome in young adulthood. The Bogalusa Heart Study. Diabetes. 2002;51:204\u20139.","journal-title":"Diabetes"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1176\/appi.ajp.159.3.394","volume":"159","author":"JG Johonson","year":"2002","unstructured":"Johonson JG, Cohen P, Kasen S, et al. Childhood adversities associated with the risk for eating disorder or weight problems during adolescents or early adulthood. Am J Psychiatry. 2002;159:394\u2013400.","journal-title":"Am J Psychiatry"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","volume":"45","author":"C Correll","year":"2006","unstructured":"Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771\u201391.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/archdischild-2011-300054","volume":"96","author":"NB Almandil","year":"2011","unstructured":"Almandil NB, Wong ICK. Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed. 2011;96:192\u20136.","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341.","journal-title":"Lancet"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"159","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;159:1686\u201396.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"16_CR26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152\u201363.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"16_CR27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, Pattens S. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomised controlled trials. Drug Saf. 2011;34(8):651\u201368.","journal-title":"Drug Saf"},{"key":"16_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M Hert De","year":"2011","unstructured":"De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144\u201358.","journal-title":"Eur Psychiatry"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/9780470693926.ch2","volume-title":"Systemic review in health care: meta-analysis in context","author":"M Egger","year":"2001","unstructured":"Egger M, Smith GB, Altman D. Systemic review in health care: meta-analysis in context. London: BMJ Publishing Group; 2001. p. 23\u201366."},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896\u2013900.","journal-title":"Lancet"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomised clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"16_CR32","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008."},{"key":"16_CR33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/cap.2006.0007","volume":"18","author":"DF Connor","year":"2008","unstructured":"Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18:140\u201356.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, et al. A placebo controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130\u20135.","journal-title":"Neurology"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2431-8-4","volume":"8","author":"W Spettigue","year":"2008","unstructured":"Spettigue W, Buchholz A, Henderson K, et al. Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatr. 2008;8:4.","journal-title":"BMC Pediatr"},{"key":"16_CR36","first-page":"1216","volume":"41","author":"MP Delbello","year":"2002","unstructured":"Delbello MP, Schwiers ML, Rosenberg HL, et al. A double blind randomised placebo controlled study of quetiapine as adjunctive treatment of adolescent mania. Psychiatry. 2002;41:1216\u201323.","journal-title":"Psychiatry"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","volume":"39","author":"RL Findling","year":"2000","unstructured":"Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509\u201316.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","volume":"62","author":"JK Buitelaar","year":"2001","unstructured":"Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239\u201348.","journal-title":"J Clin Psychiatry"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/104454601750143348","volume":"11","author":"M Bellinghen Van","year":"2001","unstructured":"Van Bellinghen M, De Troch C. Risperidone in the treatment of disturbances in children and adolescents with borderline intellectual functioning: a double-blind placebo controlled trial. J Child Adolesc Psychopharmacol. 2001;11:5\u201313.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","volume":"41","author":"R Snyder","year":"2002","unstructured":"Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026\u201336.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman MG, DeSmedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337\u201346.","journal-title":"Am J Psychiatry"},{"key":"16_CR42","doi-asserted-by":"crossref","unstructured":"McCracken JT, McGough J, Shah B, etal.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314\u201321.","DOI":"10.1056\/NEJMoa013171"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634\u201341.","journal-title":"Pediatrics"},{"key":"16_CR44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","volume":"163","author":"M Reyes","year":"2006","unstructured":"Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163:402\u201310.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"16_CR45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","volume":"21","author":"R Nagaraj","year":"2006","unstructured":"Nagaraj R, Shinghi P, Malhi P. Risperidone in children with autism: randomised, placebo-controlled, double blind study. J Child Neurol. 2006;21(6):450\u20135.","journal-title":"J Child Neurol"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","volume":"46","author":"JL Armenteros","year":"2007","unstructured":"Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit\/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46:558\u201365.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545\u201350.","journal-title":"Biol Psychiatry"},{"key":"16_CR48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","volume":"16","author":"J Luby","year":"2006","unstructured":"Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16:575\u201387.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"16_CR49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","volume":"19","author":"M Haas","year":"2009","unstructured":"Haas M, Unis AS, Armenteros J, et al. A 6 week randomized double blind placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"16_CR50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","volume":"11","author":"M Haas","year":"2009","unstructured":"Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized double blind placebo controlled study. Bipolar Disord. 2009;11(11):687\u2013700.","journal-title":"Bipolar Disord"},{"key":"16_CR51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","volume":"16","author":"E Hollander","year":"2006","unstructured":"Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16:541\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR52","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","volume":"164","author":"M Tohen","year":"2007","unstructured":"Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547\u201356.","journal-title":"Am J Psychiatry"},{"key":"16_CR53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","volume":"48","author":"L Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6 week randomised double blind placebo controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60\u201370.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.08m04726","volume":"70","author":"S Tramontina","year":"2009","unstructured":"Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder co-morbid with attention-deficit\/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756\u201364.","journal-title":"J Clin Psychiatry"},{"key":"16_CR55","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","volume":"124","author":"R Owen","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533\u201340.","journal-title":"Pediatrics"},{"issue":"11","key":"16_CR56","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, et al. A placebo controlled fixed does study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.16.665","volume":"16","author":"DH Barzman","year":"2006","unstructured":"Barzman DH, Delbello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsive and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16:665\u201370.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","volume":"166","author":"R Keefe","year":"2004","unstructured":"Keefe R, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;166:985\u201395.","journal-title":"Am J Psychiatry"},{"key":"16_CR59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.schres.2007.04.027","volume":"94","author":"MS Buchsbaum","year":"2007","unstructured":"Buchsbaum MS, Haznedar MM, Aronowitz J, et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res. 2007;94:293\u2013305.","journal-title":"Schizophr Res"},{"key":"16_CR60","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/oxfordjournals.schbul.a033413","volume":"25","author":"RA Emsley","year":"1999","unstructured":"Emsley RA, Risperidone working group. Risperidone in the treatment of first episode psychotic patients: a double blind multicentre study. Schizophr Bull. 1999;25:721\u20139.","journal-title":"Schizophr Bull"},{"key":"16_CR61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2006.09.013","volume":"89","author":"R Emsley","year":"2007","unstructured":"Emsley R, Rabinowitz J, Medori R, et al. Remission in early psychosis: rates, predictors and clinical and functional outcome correlates. Schizophr Res. 2007;89:129\u201339.","journal-title":"Schizophr Res"},{"key":"16_CR62","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","volume":"67","author":"BC Facorro","year":"2006","unstructured":"Facorro BC, Iglesias RP, Bonilla MR, et al. A practical clinical trial comparing haloperidol, risperidone and olanzapine for acute treatment of first episode nonaffective psychosis. J Clin Psychiatry. 2006;67:1511\u201321.","journal-title":"J Clin Psychiatry"},{"key":"16_CR63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/cap.2007.0089","volume":"18","author":"S Kumra","year":"2008","unstructured":"Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008;18:307\u201316.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR64","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"suppl 4","key":"16_CR65","first-page":"26","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):26\u201336.","journal-title":"J Clin Psychiatry"},{"key":"16_CR66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004850-200107000-00003","volume":"16","author":"MI Butterfield","year":"2001","unstructured":"Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Inter Clin Psychopharmacol. 2001;16:197\u2013203.","journal-title":"Inter Clin Psychopharmacol"},{"key":"16_CR67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","volume":"65","author":"MP Bogenschutz","year":"2004","unstructured":"Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104\u20139.","journal-title":"J Clin Psychiatry"},{"key":"16_CR68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","volume":"23","author":"CM Beasley","year":"2003","unstructured":"Beasley CM, Sutton VK, Hamilton SH, et al. A double blind randomized placebo controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23:582\u201394.","journal-title":"J Clin Psychopharmacol"},{"key":"16_CR69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","volume":"41","author":"G Ratzoni","year":"2002","unstructured":"Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337\u201343.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"16_CR70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/104454603322572633","volume":"13","author":"RG Ross","year":"2003","unstructured":"Ross RG, Novins D, Farley GK, et al. A 1-year open label trial of olanzapine in school age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13:301\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"16_CR71","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s007870170028","volume":"10","author":"KM Haapasalo-Pesu","year":"2001","unstructured":"Haapasalo-Pesu KM, Saarij\u00e4rvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur Child Adolesc Psychiatry. 2001;10:205\u20138.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"16_CR72","volume-title":"Mental health and behavioural disorders","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2006","unstructured":"National Institute for Health and Clinical Excellence (NICE). Mental health and behavioural disorders. London: NICE; 2006."},{"key":"16_CR73","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4): CD006569.","DOI":"10.1002\/14651858.CD006569.pub3"},{"issue":"3","key":"16_CR74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","volume":"22","author":"A Mir","year":"2008","unstructured":"Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction on aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244\u201353.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"16_CR75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0269881109358198","volume":"25","author":"KJ Aitchison","year":"2011","unstructured":"Aitchison KJ, Mir A, Shivakumar K, et al. Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. J Psychopharmacol. 2011;25(5):675\u201384. doi: 10.1177\/0269881109358198 .","journal-title":"J Psychopharmacol."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0016-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0016-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T12:00:24Z","timestamp":1688126424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0016-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0016-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}